相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia
Hind Rafei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation
Fei Yang et al.
LEUKEMIA & LYMPHOMA (2020)
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
Hirokazu Sasaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group
Josep-Maria Ribera et al.
CANCER (2019)
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
Amber C. King et al.
LEUKEMIA RESEARCH (2019)
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
Iman Abou Dalle et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
How I treat Philadelphia chromosome- positive acute lymphoblastic leukemia
Farhad Ravandi
BLOOD (2019)
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib
Firas El Chaer et al.
ACTA HAEMATOLOGICA (2019)
Epidemiology and biology of relapse after stem cell transplantation
Mary Horowitz et al.
BONE MARROW TRANSPLANTATION (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph' plus Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Maria Cristina Pirosa et al.
CHEMOTHERAPY (2018)
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant
Renzi Daniela et al.
CHEMOTHERAPY (2017)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Mar row Transplantation
Sebastian Giebel et al.
HAEMATOLOGICA (2017)
Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Gebel et al.
CANCER (2016)
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors. Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Zachariah DeFilip et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL
Farhad Ravandi et al.
BLOOD ADVANCES (2016)
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
Dae-Young Kim et al.
BLOOD (2015)
Ponatinib given for advanced leukemia relapse after allo-SCT
K. Hirschbuehl et al.
BONE MARROW TRANSPLANTATION (2015)
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
Veronica Leoni et al.
HAEMATOLOGICA (2015)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
Elias Jabbour et al.
LANCET ONCOLOGY (2015)
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia
Veronica Leoni et al.
HAEMATOLOGICA (2015)
Phase 1/2 Study of Nilotinib Prophylaxis After Allogeneic Stem Cell Transplantation in Patients With Advanced Chronic Myeloid Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Avichai Shimoni et al.
CANCER (2015)
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Eolia Brissot et al.
HAEMATOLOGICA (2015)
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
Attilio Olivieri et al.
BLOOD (2013)
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
H. Pfeifer et al.
LEUKEMIA (2013)
Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Giovanni Caocci et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
A. Spyridonidis et al.
LEUKEMIA (2012)
Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily
Giuseppe Saglio et al.
CANCER (2010)
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final resullts of the CSTIBES02 trial
Josep-Maria Ribera et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
M. Brueggemann et al.
LEUKEMIA (2010)
Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia
Evgeny Klyuchnikov et al.
ACTA HAEMATOLOGICA (2009)
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib
Mario Tiribelli et al.
LEUKEMIA RESEARCH (2009)
分享论文
